Angiotensin receptor neprilysin inhibitor in elderly with hypertension
10.12092/j.issn.1009-2501.2022.04.014
- Author:
Zheng KUAI
1
;
Xiaoyi ZHANG
1
;
Yunzeng ZOU
2
Author Information
1. Department of Geriatrics, Zhongshan Hospital, Fudan University
2. Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University
- Publication Type:Journal Article
- Keywords:
Angiotensin receptor neprilysin inhibitor;
Elderly;
Hypertension;
LCZ696
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):442-445
- CountryChina
- Language:Chinese
-
Abstract:
Angiotensin receptor/neprilysin inhibitor (ARNI) is a novel combination drug that is a dual inhibitor of angiotensin receptor and neprilysin. In June 2021, the National Medical Products Administration approved ARNI for hypertension indications. This review provides an update of current literature on ARNI in elderly hypertension.
